OREANDA-NEWS. Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces it will be holding a presentation for investors on Tuesday 21 June 2016.

The event will be held at the Black Bar, upstairs at Rocket Bar, 6 Adams Court, Old Broad Street, London, EC2N 1DX from 4.45pm for a 5.00pm start.

A presentation will be given by management and will cover an overview of the Company, where it is currently positioned and its plans for the future. This will be followed by an opportunity to network over drinks and canapes.

To register for the event, please contact motifbio@walbrookpr.com or call the Walbrook PR team below.

Motif Bio is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus).  Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.  For additional information about Motif Bio please visit www.motifbio.com.